|
|
Post by radgray68 on Jun 29, 2021 11:08:35 GMT -5
I think we can all agree that CGM's are THE tools that illustrate Afrezza's true effectiveness, yes? Well, it's only fitting that coverage for getting both in the hands of patients has been withheld. Add in step therapy, PA's and kickbacks to the middlemen and the cartels don't have to beat us OR buy us.
Meanwhile, 80% are failing. Honest question for the powers that be: With regard to diabetes, have any of you made a difference? Earned your paycheck? FDA? ADA? AMA?
Personal admission: I may have a little problem with authority......for good reason, IMO
|
|
|
|
Post by mango on Jun 30, 2021 11:18:58 GMT -5
This is very interesting. We have all known about people using Afrezza in conjunction with a pump for quickly correcting highs. What is interesting here is that this underscores the uniqueness of Afrezza’s pharmacokinetics. It’s the only insulin capable of correcting a high in real time. What is also interesting to note is when Sam told us he had forgotten to pack his basal insulin on a trip (or something to this effect) and only had Afrezza with him. Sam is a T1D. Sam ONLY used Afrezza during the duration of time he did not have access to basal insulin and he MAINTAINED excellent time in range using ONLY Afrezza. You could NEVER do that with an injectable mealtime insulin.  |
|
|
|
Post by dh4mizzou on Jun 30, 2021 11:23:49 GMT -5
"...... he MAINTAINED excellent time in range using ONLY Afrezza."
OMG. Now THAT could be a game changer !!!
|
|
|
|
Post by sportsrancho on Jun 30, 2021 15:25:29 GMT -5
If only you knew:-)
|
|
|
|
Post by morfu on Jun 30, 2021 15:59:30 GMT -5
" ...... he MAINTAINED excellent time in range using ONLY Afrezza." OMG. Now THAT could be a game changer !!! Well, beta cells produce insulin. For a type 2 patient the beta cells are there but do not produce enough insulin. With some help (mealtime insulin), they might be good enough to maintain a normal insulin level outside mealtimes for some patients. More importantly it could be possible to reduce high performance/high stress intervals for the remaining cells and even recover functionality with the right treatment And I believe Afrezza can be a key factor there.. for some patients/early stages.
|
|
|
|
Post by mango on Jun 30, 2021 17:14:51 GMT -5
" ...... he MAINTAINED excellent time in range using ONLY Afrezza." OMG. Now THAT could be a game changer !!! Well, beta cells produce insulin. For a type 2 patient the beta cells are there but do not produce enough insulin. With some help (mealtime insulin), they might be good enough to maintain a normal insulin level outside mealtimes for some patients. More importantly it could be possible to reduce high performance/high stress intervals for the remaining cells and even recover functionality with the right treatment And I believe Afrezza can be a key factor there.. for some patients/early stages.
T2D isn’t a basal problem, it’s a prandial problem. On top of that, T2D have a loss of the first-phase insulin response. The PFIR is essential to maintain glucose homeostasis, beta cell and metabolic memory, essential communication with the liver, and other physiological processes. It’s medically incorrect to treat T2D with basal insulin. T2D need Afrezza to restore the PFIR and thus post-prandial glucose homeostasis. |
|
|
|
Post by sportsrancho on Jul 5, 2021 14:10:09 GMT -5
✨We thought you might appreciate a little up-date on Afrezza Assist…👍🏻 #MannkindCorporation #Afrezza #VdexDiabetes “We want to say how much we appreciate the Mannkind reps that we work with and the “Afrezza Assist” program through which the company provides free product to patients. It’s a great start. It certainly helps Vdex get more patients on the product. Many times, it helps us make the case to a reluctant insurance company that they should cover the product, especially when a patient has a history of an intractable HbA1c of say, 11 and then when switched to Afrezza, has that HbA1c drop to below 7. This happens a lot. We remain committed to benefiting people with diabetes seeking better, safer, easier control of their disease.” Sincerely, Vdex Diabetes afrezzaassist.com/ |
|
|
|
Post by cretin11 on Jul 5, 2021 15:35:15 GMT -5
Outstanding, thanks for that update!
|
|
|
|
Post by nylefty on Jul 8, 2021 15:19:02 GMT -5
|
|
|
|
Post by mymann on Jul 8, 2021 17:14:22 GMT -5
Is mnkd deliberately giving misinformation about Medicare coverage of affreza? I don't see anything about affreza coverage other than CGM coverage.
|
|
|
|
Post by peppy on Jul 8, 2021 17:27:17 GMT -5
quote: the Medicare Advantage plans available in my area. There are 34 such plans. reply: times 50. Off topicIs this really the best way to run health care? or a good way to run pay to play? Wasn't there something about a really good health care plan that was cheaper going to be presented in a couple of weeks? A couple of weeks every time.  |
|
|
|
Post by hellodolly on Jul 8, 2021 17:40:00 GMT -5
Is mnkd deliberately giving misinformation about Medicare coverage of affreza? I don't see anything about affreza coverage other than CGM coverage. My take on the policy change is that there were restrictions on patients forced to choose between a CGM to manage their diabetes care, with draconian injections or the pump, but not inhaled. It looks like that has now been waived and persons can choose both, a CGM and the inhaled device that allows the delivery of Afrezza. Per the PR: " Effective July 18, the criteria change lifts the restriction on patients of having to choose between the two diabetes tools...MannKind requested that the Durable Medical Equipment (DME) MACs reconsider the existing language in the LCD: Glucose Monitors (L33822) to include use of inhaled insulin. Previously, the criteria defined patients as taking insulin either with multiple daily injections or an insulin pump. The amended definition now includes a patient that takes insulin with inhalation as an alternative." But, that's how I see it. CGM users have an added choice of using an inhaled insulin now. Not a deliberate misinformation campaign...not by a mile. |
|
|
|
Post by mnkdfann on Jul 8, 2021 17:59:29 GMT -5
|
|
|
|
Post by sayhey24 on Jul 8, 2021 18:36:21 GMT -5
Here is the interesting one - The beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a continuous subcutaneous insulin infusion (CSII) pump; The current SoC for the T2 going on insulin would be once a day basal. This sure does not help the CGM vendors like Dexcom. If however the CGM vendors push PCPs to instead subscribe afrezza by demonstrating better control and better long term out comes, afrezza meets the 3x daily requirement. It sure seems this opens up a new huge market for the CGM vendors and a whole new huge sales force for afrezza who might actually be able to sell at the corporate headquarters who are now controlling many of the PCPs. The CGM vendors just need to figure out a way to either get afrezza covered by insurance or cheap enough nearly everyone can afford. Maybe they can buy direct from MNKD and sell a combo sensor/afrezza package. I wonder if medicare would cover that? |
|
|
|
Post by nylefty on Jul 8, 2021 19:01:49 GMT -5
Is mnkd deliberately giving misinformation about Medicare coverage of affreza? I don't see anything about affreza coverage other than CGM coverage. Not a deliberate misinformation campaign...not by a mile. Not misleading to me or you, but too many people on this board and elsewhere came away thinking that "Medicare" will now cover Afrezza, which is not the case at all. |
|
